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Abstract 
Diabetes mellitus (DM) is a frequently encountered disease with important morbidity and mortality. The aim of this 
study is to document the importance of 1,5-anhydroglucitol (1,5-AG) for the diagnosis of prediabetes and DM, as well 
as to compare the 1,5-AG with other glycemic markers in order to understand which one is the better diagnostic tool. 
Between April 2012 and December 2012, 128 participants enrolled in the study. Participants were split into five groups 
that are IFG, IGT, IFG+IGT, diabetic and control groups by their OGTT results. The diagnostic value of markers was 
compared by ROC (receiver operating characteristic) method. The mean serum 1,5-AG levels in the diabetic group 
(33.38 nmol/ml) were lower than, IFG (59.83 nmol/ml), IGT (54.44 nmol/ml), IFG+IGT (51.98 nmol/ml) and control 
groups (73.24 nmol/ml). When analyzed in the total study population serum 1,5-AG levels did not differ by gender sig-
nificantly. When analyzed in the total study population, 1,5-AG correlates inversely with age significantly (p = 0.036). 
In subgroup analysis, in the control group, serum 1,5-AG level was also inversely correlated with age (p = 0.087). The 
best marker for the diagnosis of prediabetes and DM was fasting plasma glucose (FPG). 1,5-AG was not found to be 
effective for the diagnosis of DM. This study, contributes to our knowledge of the efficiency and cut-off values of 1,5-
AG for the diagnosis of prediabetes and DM. In future, there is a need for larger studies with more standardized and 
commonly used measurement methods for 1,5-AG, in order to evaluate the efficiency of 1,5-AG for the diagnosis of 
prediabetes and DM.
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Background
Diabetes mellitus (DM) is a syndrome which insulin 
function or secretion or both impaired (Arrellano-Valdez 
et al. 2014). Prediabetes is the state between the normal 
blood glucose level and DM. The mechanism of predia-
betes is insulin resistance and pancreatic beta cell dis-
function (Pour and Dagogo-Jack 2011). Prediabetes is 
a risk for DM and cardiovascular disease (Twigg et  al. 
2007). Prediabetes has two basic types. One of them is 
IFG (impaired fasting glucose) and the other is IGT (glu-
cose intolerance). In present fasting glucose, randomly 
plasma glucose with DM symptoms and 75 g OGTT 
is widely used for the diagnosis of DM. In 2009, ADA 
(American Diabetes Association) stated that HbA1c 
(glycated hemoglobin) could be used for DM diagno-
sis (International Expert Committee 2009). Glycated 
hemoglobin shows the average plasma glucose levels 
for the past 2–3  months. It is an advantage that fasting 
is not required for measurement of the glycated hemo-
globin (McCance et al. 1994). Some authors suggests the 
use of the glycated hemoglobin in DM diagnosis (Kim 
et  al. 2011; Saudek and Brick 2009), whereas the other 
do not agree this idea because of the low sensitivity lev-
els of glycated hemoglobin (Selvin et  al. 2009; Malkani 
and Mordes 2011). Fructosamine is created by the non-
enzymatic glicolization of serum proteins such as albu-
mine. Fructosamine shows the average plasma glucose 
of past 1–3 weeks. Glycated hemoglobin is more widely 
used for to measure plasma glucose levels; however 
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fructosamine is superior to glycated hemoglobin in 
some conditions like hemoglobinopathy which glycated 
hemoglobin could be mistaken (Armbruster 1987; Koch 
1996). HOMA-IR is actually used for to detect the insu-
lin resistance (Yang et al. 2013). In some conditions that 
glycated hemoglobin can be wrong, that other indicators 
such as 1,5-anhydroglucitol (1,5-AG) is suggested to be 
used. 1,5-AG is a monosaccaride that exists in food. It is 
filtrated through kidneys and absorbed by renal tubules. 
The glucose afinity of proximale tubules is higher than 
the afinity to 1,5-AG. Because of this reason in the hyper-
glisemic state when glycosuria occurs, the reabsorption 
of 1,5-AG decreases and it is excreted by urine. So, the 
levels of plasma 1,5-AG decreases when the blood glu-
cose level increases (Homa and Majkowska 2010; Stickle 
and Turk 1997). 1,5-AG shows the glucose levels of past 
10–14 days (Stettle et al. 2008). In some studies 1,5-AG 
suggested as an indicator of blood glucose levels (Umeda 
et al. 1991). There are also some studies that suggest 1,5-
AG can be used as a tool for DM diagnosis (Shah et al. 
2009; Frattali and Wolf 1994)
Aim
The aim of this study is to document the importance of 
1,5-AG in the diagnosis of prediabetes and DM and com-
pare 1,5-AG with glycated hemoglobin, fructosamine, 
fasting glucose and HOMA-IR in order to understand 
which one is the better diagnostic tool.
Methods
The study is carried out in Ufuk University Dr.Rıdvan 
Ege Hospital in the city of Ankara, Turkey. Between 
April 2012 and December 2012, 128 patients who were 
performed 75 g OGTT, involved in study. The patients 
were joined the study from policlinics of internal medi-
cine and endocrinology. The criteria to join the study 
were being 25 year old or older and having indication for 
OGTT. The exclusion criteria were, pregnancy, kidney 
disease (creatine levels 3 mg/dl or higher), liver disease, 
malabsorption syndromes, usage of steroids, polygala, 
tenuifolia, senega, alpha-glucosidase inhibitors, anemia, 
DM diagnosis before, usage of antidiabetic drugs and 
history of gastrectomy. This study is a cross-sectional 
analysis of an observational study. Ufuk University ethical 
board approval has been received. All participants gave 
informed consent. All of the ethical considerations have 
been strictly followed in accordance with the Helsinki 
declaration. All of the measurements were performed 
within a few days after the indication for OGTT. Par-
ticipants who agreed to attend study gave blood samples 
between hours 08.00–09.00 after minimum 10 h of fast-
ing. 75 g OGTT was performed and the patients were 
divided into 5 groups according to OGTT World Health 
Organization (WHO) criteria which were IFG, IGT, 
IFG+IGT, DM and control groups. From fasting glucose 
samples Glycated hemoglobin, fructosamine, total cho-
lesterol, LDL, HDL, trigliseride, BUN, creatinine, CBC, 
AST, ALT, albumine, total protein, sedimentation, fast-
ing insulin, fasting c-peptide levels were detected. Blood 
samples from each patient taken for 1,5-AG levels had 
stored at −83 cantigrat degree for the analysis day with 
ELISA method. Each patients arterial blood pressure 
were measured and demographic data were recorded. 
Waist circumference measurement executed from half 
of distance between inferior costa and spina iliaca ante-
rior superior. Body mass index and HOMA-IR (fasting 
plasma glucose (FPG) (mg/dl)  ×  fasting plasma insulin 
(μ/ml)/405) were calculated for each participant. The 
pancreas B cell function were calculated with the for-
mula of 360 ×  fasting plasma insulin (μ/ml)/FPG (mg/
dl) −63 %. The analysis of blood samples were performed 
at Ufuk University Dr. Rıdvan Ege Hospital Biochemis-
try Department Laboratuary. Glycated hemoglobin was 
measured with “Agilent 1100 Series” with “High Pressure 
Likid Chromatography” method whereas fructosamine 
was measured with “Cobas Integra 400 Plus” with spec-
trophotometric method. BUN, creatinine, HDL, LDL, 
trigliseride, total cholesterol, albumine, total proteine 
blood samples were detected with “Cobas Integra 800” 
with spectrophotometric method. The analysis of plasma 
samples for glucose levels were executed with hexoci-
nase method by “Cobas Integra 800”. 1,5-AG is measured 
with “Cusabio Human 1,5-anhydroglucitol ELISA Kit” by 
“DSX Automated Elisa System” machine.
Statistical analyses
Statistical analyzis executed with “IBM SPSS Statistics 
20” programme. Firstly the distribution type of data ana-
lyzed. Data which showed normal distribution patern 
analyzed with ANOVA or T Test methods and results 
were presented as mean ±  standard deviation. The dual 
comparison of the data which showed normal distrubu-
tion, TUKEY method was used. Data which did not show 
normal pattern were analyzed with Cruscal-Wallis or 
Mann–Whitney U methode and results were presented 
as mean and 95 % confidence interval. Dual comparison 
of data which do not showed normal pattern executed 
with “Bonferroni corrected Mann–Whitney U” methode. 
Spearman corelation analyzes performed to investigate 
serum 1,5-AG and other variables. In the comparison of 
the power of the diagnostic tools, ROC (Receiver Oper-
ating Characteristics) curve is used. Threshold level of 
the diagnostic tools determined as the point in the ROC 
curve which is closest to sensitivity value 100  % and 
false positive value 0  %. HOMA-IR calculated as “FPG 
(mg/dl)  ×  fasting insulin (μU/ml)/405” and HOMA-B 
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calculated as “360 x fasting insulin (μU/ml)/(FPG (mg/
dl)-63)”. Statistical significance point set to p < 0.05.
Results
Between April 2012 and December 2012, 128 participants 
who applied to endocrinology or internal medicine clin-
ics of Ufuk University Dr. Rıdvan Ege Hospital, enrolled 
in this study. All participants had indication for 75 g 
OGTT and gave informed consent. Mean age of partici-
pants were 53.0 ± 12.2. 48 participant (37.5 %) were male, 
80 participant (62.5 %) were female. IFG, IGT, IFG+IGT 
groups together evaluated as “prediabetic group”. Con-
trol group has the most participant with 38 people. Mean 
age of participants was highest in diabetic group. Distri-
bution of participant according to gender was not sig-
nificantly different between groups. Data of participants 
were described in Table  1. We investigated the 1,5-AG 
levels of participants in control, prediabetes, DM groups. 
1,5-AG levels of prediabetic group was higher than dia-
betic group (p = 0.039). Also, 1,5-AG levels were higher 
in control group than prediabetic group (p = 0.064). We 
examined fructosamine and glycated hemoglobin levels 
in control, prediabetic and diabetic groups. Mean plasma 
glycated hemoglobin levels were higher in prediabetes 
group than control group (p < 0.001). Also, plasma gly-
cated hemoglobin levels in DM group were higher than 
prediabetes group (p  <  0.001). Mean serum fructosa-
mine levels were higher in prediabetes group than con-
trol group (p =  0.013). Also, mean serum fructosamine 
levels were higher in DM group than prediabetes group 
(p  =  0.003). We investigated the difference of plasma 
1,5-AG levels according to gender. There is no significant 
difference of blood 1,5-AG levels according to gender 
(p = 0.813). We investigated the 1,5-AG levels according 
to age. In the total study population 1,5-AG levels found 
inversly related to age (p = 0.036). In subgroup analysis, 
the most significant inverse correlation of 1,5-AG and age 
found in control group (p = 0.087). When genders were 
separetely analyzed, in female cases the inverse correla-
tion between age and 1,5-AG was significant (p = 0.035), 
however in male cases this correlation was not significant 
(p = 0.637). We examined the relationship between 1,5-
AG and 2  h plasma glucose levels however we did not 
find any significant relationship between 1,5-AG and 
2  h plasma glucose. Then, we evaluated and compared 
the FPG, glycated hemoglobin, fructosamine, 1,5-AG 
and HOMA-IR in diagnosis of prediabetes. Participants 
who underwent OGTT evaluated according to WHO 
criteria. 68 cases labelled as prediabetes. Table  2 shows 
the comparison of FPG, HbAac, fructosamine, 1,5-AG 
and HOMA-IR as a diagnostic tool in prediabetes. FPG 
has the largest area under curve. Glycated hemoglobin, 
fructosamine, HOMA-IR and 1,5-AG follows FPG 
respectively. Fructosamine and HOMA-IR had the same 
area under curve. Optimal threshold value for diagnostic 
tools in prediabetes diagnosis provides 72.1  % sensitiv-
ity, 86.6 % specificity for FPG. The other values listed in 
Tables 2 and 3. We evaluated and compared the FPG, gly-
cated hemoglobin, Fructosamine, 1,5-AG and HOMA-
IR for the diagnosis of DM. Participants who underwent 
OGTT evaluated according to WHO criteria. 22 cases 
labelled as DM. Table below shows the comparison of 
FPG, HbAac, fructosamine, 1,5-AG and HOMA-IR as 
a diagnostic tool in DM. FPG has the largest area under 
curve. Glycated hemoglobin, fructosamine, HOMA-IR 
and 1,5-AG follows FPG respectively. Area under curve 
of 1,5-AG remained below of the reference line (Fig. 1). 
The other values listed in Tables  2 and  3. We evaluated 
and compared the FPG, glycated hemoglobin, fructosa-
mine, 1,5-AG and HOMA-IR in diagnosis of glucose 
intolerance (DM+prediabetes). Participants who under-
went OGTT evaluated according to WHO criteria. 22 
cases labelled as DM and 68 cases labelled as DM. Table 2 
shows the comparison of FPG, HbAac, fructosamine, 1,5-
AG and HOMA-IR as a diagnostic tool in DM and pre-
diabetes. FPG has the largest area under curve. Glycated 
hemoglobin, fructosamine, HOMA-IR and 1,5-AG fol-
lows FPG respectively. The other values listed in Tables 2 
and 3.
Discussion
Early diagnosis in prediabetes and DM can reduce the 
mortality and morbidity of the disease. The reference 
test for the diagnosis of prediabetes and DM is OGTT 
according to the WHO recommendations. For screeen-
ing of glucose intolerance, 2  h post-OGTT glucose 
level is used. Fasting condition of the patient is needed 
for the OGTT and FPG tests. For this reason applica-
tion of these methods can be challenging for doctor and 
patient. Also if the patient is not in fasting condition, it 
is required to come to hospital for a second time, thus 
making the situation tiring and expensive. Therefore, 
alternative diagnostic tools which do not reguire fast-
ing condition, may be preferred. Glycated hemoglobin, 
fructosamine, 1,5-AG are diagnostic tools which do not 
reguire fasting (Shah et  al. 2009). Many studies have 
investigated the role of the 1,5-AG in DM. In some stud-
ies, the efficiency of 1,5-AG found higher than glycated 
hemoglobin whereas more studies suggests glycated 
hemoglobin is better because 1,5-AG has wide range of 
normal distrubution. As a result, the role of 1,5-AG in 
diagnosis of DM remained uncertain (Robertson et  al. 
1993; Shirasaya et  al. 1999; Yamanouchi et  al. 1991; 
Yamanouchi et al. 2001).
In many reports, it is found that there is a statisti-
cally significant inverse relationship between plasma 
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1,5-AG level and post OGTT second hour plasma glu-
cose (Yamanouchi et al. 1988; Goto et al. 2011). However 
in our study we did not find any relationship between 
plasma 1,5-AG and post OGTT second hour glucose lev-
els. The cause of this can be explained by the relatively 
low number of participants in our study in comparison 
to the other studies. There are some studies that investi-
gates the role of 1,5-AG in the diagnosis of DM and pre-
diabetes. Our study has similarities and differences from 
these studies. Firstly in our study, the mean plasma 1,5-
AG levels were found higher in control group than pre-
diabetic group. Also the 1,5-AG levels were found higher 
in prediabetic group than diabetic group (Shirasaya et al. 
1999; Won et  al. 2009). In many other studies it is sug-
gested that the normal distribution range of 1,5-AG is 
so wide that it limits the usage of 1,5-AG in DM screen-
ing (Robertson et al. 1993; Yamanouchi et al. 1991; Won 
et  al. 2009). Similarly, 1,5-AG has distributed in a wide 
range in our study, thus with the additive effect of limited 
case numbers we did not get statistical significance. The 
importance of the glisemic markers in diagnosis can be 
investigated many ways. Selectivity index or ROC curve 
method can be used (Koch 1996; Shirasaya et  al. 1999; 
Yamanouchi et al. 1991; Goto et al. 2011). We preferred 
the ROC curve in our study. In a study conducted by 
Yamanouchi et  al. selectivity index was used to investi-
gate the most important marker in DM diagnosis. 1,5-AG 
was found as the best marker, glycated hemoglobin and 
fructosamine followed it respectively (Yamanouchi et al. 
1991). In another study, the most important markers 
Table 1 Data of participants
Data which do not show normal pattern analyzed with Cruscal-Wallis or Mann–Whitney U methode and results were shown mean and 95 % confidence interval. Dual 
comparison of data which do not showed normal pattern executed with “Bonferroni corrected Mann–Whitney U” methode. Near data (×) plot put to indicate which 
group was significantly different against other group. (1. Groups named with numbers as: Control group 1, IFG group 2, IGT group 3, IFG+IGT group 4, and DM group 
5). (2. Fasting insulin value was not significant in any comparison)
* Data which showed normal distribution patern analyzed with ANOVA or T Test methode and results showed as mean ± standard deviation. The dual comparison of 
the data which showed normal distrubution, TUKEY methode is used
Groups (1) CONTROL (n = 38) (2) IFG (n = 24) (3) IGT (n = 23) (4) IFG + IGT (n = 21) (5) DM (n = 22) p value
Age *(4,5)*50.1 ± 9.0 *(4,5)*48.5 ± 13.2 *(5)*51.6 ± 11.5 *(1,2)*57.4 ± 11.5 *(1,2,3)*60.3 ± 13.4 0.002 
Gender (M/F) 14/24 7/17 10/13 8/13 9/13 0.881 











30.min PG (mg/dl) *(2,4,5)*150.2 ± 27.4 *(1,5)*175.1 ± 39.9 *(4,5)*153.7 ± 28.7 *(1,3,5)*183.3 ± 23.2 *(1,2,3,4)*215.9 ± 60.6 <0.001 
60.min PG (mg/dl) *(2,3,4,5)*142.9 ± 41.0 *(1,4,5)*182.4 ± 49.5 *(1,5)*185.7 ± 36.1 *(1,2,5)*209.9 ± 29.4 *(1,2,3,4)*275.3 ± 68.0 <0.001 
90.min PG (mg/dl) *(3,4,5)*117.3 ± 30.2 *(3,4,5)*140.3 ± 33.5 *(1,2,5)*173.3 ± 36.5 *(1,2,5)*195.9 ± 30.4 *(1,2,3,4)*282.3 ± 87.3 <0.001 











HbA1c (%) *(2,4,5)*5.29 ± 0.48 *(1,4,5)*5.79 ± 0.41 *(4,5)*5.63 ± 0.57 *(1,2,3,5)*6.22 ± 0.86 *(1,2,3,4)*6.72 ± 0.99 <0.001 
Fructosamine (µmol/l) *(5)*227.2 (221.2–
233.3)
238.0 (228.0–248.0) *(5)*229.6 (219.3–
239.9)





73.2 (27.5–118.9) 59.8 (39.4–80.1) 54.4 (32.1–76.7) 51.9 (34.6–69.3) 33.3 (22.2-44.5) 0.189 
Total cholesterol (mg/dl) 196.0 ± 37.6 193.2 ± 36.4 199.2 ± 32.0 204.2 ± 29.6 192.0 ± 35.2 0.783 
LDL (mg/dl) 123.0 ± 29.8 119.6 ± 32.9 126.7 ± 22.7 128.2 ± 25.4 116.9 ± 31.2 0.664 
HDL(mg/dl) 47.1 ± 13.7 50.2 ± 13.5 42.1 ± 13.7 52.1 ± 18.2 44.4 ± 11.6 0.124 
Triglyceride (mg/dl) 134.2 (113.3–155.2) 125.3 (100.5–150.1) 175.3 (130.1–220.5) 139.7 (101.2–178.2) 168.7 (125.7–211.8) 0.380 
Fasting insulin (µu/ml) 15.00 (9.73–20.27) 16.27 (13.19–19.36) 11.54 (8.92–14.16) 15.51 (12.70–18.33) 14.31 (11.58–17.04) 0.030 
Fasting c-peptide (ng/ml) 3.44 (2.92–3.97) 3.80 (3.10–4.51) *(5)*2.98 (2.54–3.42) 3.44 (3.08–3.81) *(3)*3.76 (3.43–4.09) 0.021 
HOMA-IR *(2,4,5)*3.37 
(2.10–4.63)
*(1,3)*4.28 (3.43–5.13) *(2,4,5)*2.63 
(2.02–3.25)
*(1,3)*4.10 (3.35–4.86) *(1,3)*4.55 (3.47–5.63) <0.001 
HOMA β *(5)*208.1 (149.1–
267.2)
136.7 (111.4–162.0) 144.1 (113.4–174.7) 127.9 (104.3–151.6) *(1)*93.1 (73.3–112.9) <0.001 
Systolic BP (mmHg) 122.1 (117.4–126.7) 127.0 (115.6–138.5) 124.7 (116.3–133.2) 129.5 (120.1–138.9) 124.0 (117.1–131.0) 0.809 
Diastolic BP (mmHg) 78.2 (75.1–81.4) 79.5 (74.0–85.0) 78.6 (73.2–84.1) 80.1 (74.2–86.0) 74.5 (69.8–79.2) 0.598 
Mean BP (mmHg) 92.8 ± 10.7 95.4 ± 17.0 94.0 ± 14.4 96.6 ± 14.5 91.0 ± 11.0 0.670 
Height (cm) 162.9 ± 7.8 164.8 ± 8.1 164.6 ± 9.5 162.6 ± 7.9 162.0 ± 9.7 0.748 
Weight (kg) 74.8 ± 14.7 84.2 ± 17.6 72.4 ± 13.8 78.5 ± 17.0 79.0 ± 16.7 0.099 
Body mass index *(2,4,5)*26.2 ± 5.2 *(1,3)*30.9 ± 5.7 *(2,5)*26.6 ± 4.4 *(1)*29.6 ± 6.1 *(1,3)*30.2 ± 7.1 0.004 
Waist circumference (cm) 91.0 ± 12.2 97.9 ± 10.6 88.3 ± 10.4 92.8 ± 13.6 94.0 ± 11.9 0.069 
Page 5 of 8Malkan et al. SpringerPlus  (2015) 4:587 
found as FPG, 1,5-AG, glycated hemoglobin, and fruc-
tosamine respectively (Shirasaya et al. 1999). In a differ-
ent study the most important markers in DM screening 
found as glycated hemoglobin followed by 1,5-AG, FPG 
and HOMA-IR (Koch 1996). In our study the area under 
curve of 1,5-AG was lower than reference line so it is not 
suitable to use it as a marker of diagnosis of DM. In our 
study the most important marker was found as FPG in 
diagnosis for prediabetes, DM and glucose intolerance. 
The FPG is an important diagnostic tool in DM and it 
should be preferred as first test in screening of prediabe-
tes and DM. In our study glycated hemoglobin was found 
as best marker for prediabetes and DM diagnosis, which 
does not require fasting state. Recently, glycated hemo-
globin is suggested as a marker of DM which could be 
used alone because of the improvements in standardi-
zation of measurement techniques. Our study supports 
this issue, as we found Glycated hemoglobin as the sec-
ond valuable marker in the DM diagnosis. In our study, 
1,5-AG did not found as valuable a diagnostic marker 
in DM and it was found as the least valuable marker in 
prediabetes and glucose intolerance. The small number 
of samples compared to the wide distribution range can 
be the reason for that finding. In a study, the efficiency 
of 1,5-AG, glycated hemoglobin and fructosamine in pre-
diabetes and DM compared with optimal threshold lev-
els (Shirasaya et al. 1999). Optimal threshold levels were 
decided as the point on the ROC curve which is near-
est to 100 % sensitivity and 0 % false positivity. Accord-
ing to this, when 104  nmol/ml was taken as threshold 
for 1,5-AG, 83.8 % sensitivity and 84.6 % specificity val-
ues were obtained for type 2 DM diagnosis. When 5.6 % 
was taken as threshold for glycated hemoglobin, 83.8  % 
sensitivity and 79.4  % specificity values were obtained 
for type 2 DM diagnosis. When 256 µmol/l was taken as 
threshold for fructosamine, 70.3 % sensitivity and 79.9 % 
specificity values were obtained for type 2 DM diagnosis 
(Shirasaya et al. 1999). In the same study the thresholds 
were calculated for type 2 DM+IGT. When 134  nmol/
ml was taken as threshold for 1,5-AG, 62.7 % sensitivity 
and 61.0 % specificity values were obtained. When 5.4 % 
Table 2 Evaluation and  comparison of  FPG, glycated 
hemoglobin, fructosamine, 1,5-AG, HOMA-IR in  prediabe-
tes, DM and glucose intolerance diagnosis
Total study population (128 patients) was analyzed for the evaluation of the 
markers as a diagnostic tool for DM and glucose intolerance
a DM patients were excluded (106 patients were analyzed) for the evaluation of 
the markers as a diagnostic tool for Prediabetes
Diagnostic tools Area under curve
Prediabetesa DM Glucose 
intolerance
FPG 0.867 0.880 0.889
Glycated hemoglobin 0.775 0.848 0.815
Fructosamine 0.646 0.761 0.696
1,5-AG 0.609 0.405 0.582
HOMA-IR 0.646 0.683 0.683
Table 3 The comparison of sensitivity and specificity of threshold values of diagnostic tools for prediabetes, DM and glu-
cose intolerance diagnosis
Total study population (128 patients) was analyzed for the evaluation of the markers as a diagnostic tool for DM and glucose intolerance
a Threshold value for each diagnostic tool calculated as the nearest point of ROC curve that sensitivity 100 %, false positivity is 0 %
b DM patients were excluded (106 patients were analyzed) for the evaluation of the markers as a diagnostic tool for Prediabetes
Diagnostic tool Optimal threshold valuea Sensitivity Specificity
Prediabetesb FPG (mg/dl) 96.50 0.721 0.868
Glycated hemoglobin (%) 5.60 0.706 0.816
Fructosamine (µmol/l) 230.50 0.676 0.579
1,5-AG (nmol/ml) 38.79 0.618 0.711
HOMA-IR 3.00 0.618 0.684
DM FPG (mg/dl) 112.50 0.727 0.953
Glycated hemoglobin (%) 5.99 0.864 0.726
Fructosamine (µmol/l) 249.50 0.727 0.755
1,5-AG (nmol/ml) 30.97 0.591 0.443
HOMA-IR 3.21 0.818 0.585
Glucose intolerance FPG (mg/dl) 97.50 0.744 0.947
Glycated hemoglobin (%) 5.60 0.767 0.816
Fructosamine (µmol/l) 233.50 0.656 0.632
1,5-AG (nmol/ml) 33.22 0.633 0.658
HOMA-IR 3.00 0.678 0.684
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was taken as threshold for glycated hemoglobin, 53.2  % 
sensitivity and 68.6  % specificity values were obtained. 
When 244  µmol/l was taken as threshold for fructosa-
mine, 61.2 % sensitivity and 55.4 % specificity values were 
obtained (Shirasaya et al. 1999). In another study, thresh-
olds of 1,5-AG, glycated hemoglobin, fructosamine were 
calculated by selectivity index (Yamanouchi et al. 1991). 
When 85.2 nmol/ml was taken as threshold for 1,5-AG, 
84.2  % sensitivity and 93.1  % specificity values were 
obtained for DM diagnosis. When 6.2  % was taken as 
threshold for glycated hemoglobin, 67.5 % sensitivity and 
92.7  % specificity values were obtained for DM diagno-
sis (Yamanouchi et al. 1991). In a different study, in type 
2 DM screening of insulin resistant subgroup, threshold 
level for 1,5-AG was taken as 103.56 nmol/ml which gives 
96 % sensitivity and 88 % specificity values (Koch 1996). 
In the total study population, the threshold value of the 
glycated hemoglobin was taken as 5.7 % which gives 86 % 
sensitivity and 85 % specificity. In the total study popula-
tion, the threshold value of HOMA-IR was taken as 7.9 
which give 62 % sensitivity and 70 % specificity. Again in 
the total study population, the threshold value of FPG 
was taken as 104 mg/dl which gives 88 % sensitivity and 
93 % specificity (Koch 1996). In our study we have inves-
tigated markers for prediabetes, DM and glucose intoler-
ance diagnosis. After the results, we understand 1,5-AG 
is not a suitable marker for the diagnosis of DM. Also, 
the effectiveness of 1,5-AG was the lowest in the diagno-
sis of prediabetes and glucose intolerance. These findings 
opposed the past studies in literature. There can be sev-
eral reasons for this. Firstly, other studies demonstrated 
in much larger patient cohorts. Secondly, the plasma 1,5-
AG has a wide normal distribution range and our patient 
cohort was relatively small for this wide distribution 
range. Thirdly, 1,5-AG measurement technic and equip-
ments differs between studies. Lastly, all study partici-
pants had an indication for OGTT testing which means 
that the control group was also selected in the basis of 
diabetes risk, thus explaining the weaker discriminatory 
results as compared to other studies. In our study all 
measurements were performed a few days after the indi-
cation for OGTT. Therefore we have prevented our study 
data to be influenced from possible lifestyle changes by 
participants after hearing the indication for “diabetes 
testing”. In the literature there are different threshold 
levels of 1,5-AG for DM diagnosis. These values dif-
fer between studies and there is no consensus on these 
values. Values in our study differ from other studies too. 
There could be several reasons for this. Firstly, there can 
be all reasons that are mentioned above (size of patient 
cohorts, wide distribution range, etc.). Secondly, plasma 
1,5-AG levels could differ due to eating habits and race 
Fig. 1 Comparison of markers for the diagnosis of DM
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(Herman et al. 2009; Koga et al. 2010). However there is 
no study about 1,5-AG for DM diagnosis in our country 
which we could refer. As a result, there is no consensus 
on 1,5-AG threshold levels for DM and prediabetes, and 
our study contributes literature by offering threshold val-
ues for 1,5-AG in the diagnosis of DM, prediabetes and 
glucose intolerance.
To conclude, although there are several studies in the 
literature about the relationship between 1,5-AG and DM 
diagnosis; our study is the first study about this issue that 
is demonstrated in our country. Also, this is first study 
about in our country that is performed clinically and pro-
spectively. In respect to this, our study may represent the 
threshold values of 1,5-AG in our country that can be 
referred by other studies that will be conducted future. 
The limitations of our study was the relatively small 
patient cohort compared to wide distribution range of 
1,5-AG.
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